Viewing nowCombinationSitdyammate Tablet 50/850 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Donghwa Pharmaceutical Co., Ltd.

MFDS item code 202204589 · Approved 2022.12.21 · Insurance code 642707430
Improvement of glycemic control in type 2 diabetes mellitus
This medication helps control blood sugar levels in patients with type 2 diabetes by using sitagliptin and metformin together. It is used to effectively manage blood sugar when combined with diet and exercise. It is utilized to stabilize blood sugar levels and alleviate the symptoms of diabetes.
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medication should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy, or for patients whose blood glucose is not adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Receive This Medication). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medication may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to assess the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medication. Any change in the treatment regimen for type 2 diabetes may affect blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medication because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medication).
This medication contains both sitagliptin and metformin, which help in controlling blood sugar levels. First, when taking this medication, severe allergic reactions may occur; therefore, if symptoms such as hives, rash, or breathing difficulties occur, stop taking the medication immediately and seek medical attention. Additionally, pancreatitis, which is inflammation of the pancreas, may occur rarely; if symptoms such as abdominal pain, nausea, or vomiting appear, inform a doctor promptly. Metformin included in this medication can be dangerous for patients with impaired kidney function, especially in cases of moderate or severe impairment. Do not take this medication during acute conditions like dehydration, severe infections, heart attack, or shock. If you are scheduled to undergo tests using iodine contrast agents, temporarily stop taking this medication before and after the tests, and resume only after confirming normal kidney function. Women who are pregnant or may become pregnant, and those who are breastfeeding should not take this medication. During the course of taking this medication, irregular meals or intense exercise, and interactions with other medications may cause hypoglycemia or lactic acidosis, so caution is advised. In particular, the metformin component can cause lactic acidosis, a severe metabolic disorder; if symptoms such as breathing difficulties, muscle pain, weakness, or abdominal pain occur, seek medical attention immediately. Regular assessments of kidney function and blood tests should be conducted during treatment, and vitamin B12 deficiency may occur, requiring supplementation if necessary. Avoid alcohol as it may increase the risk of side effects from this medication. When undergoing surgery, stop taking this medication 48 hours prior to surgery and resume only after confirming normal kidney function post-surgery. If taking other hypoglycemic agents or insulin with this medication, there may be an increased risk of hypoglycemia, and dosage adjustments may be required as directed by a physician. Finally, the safety and efficacy of this medication in children under 18 years of age have not been established, so it should not be used in this population.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container that is air-tight, preferably at room temperature between 1 and 30 degrees Celsius. This will maintain the efficacy of the medication and prevent degradation.
Oval film-coated tablet in dark pink color
56 tablets/box [(14 tablets/PTP x 4)], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Donghwa Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.